Tag: COVAXIN 2022 peer review

COVAXIN is Safe, Highly Immunogenic in 2-18 Years Old – The Lancet Review

Bharat Biotech today announced COVAXIN Latest Peer Review published in the Lancet Infectious Disease Journal . The company…